EPIRUS Biopharma reports Q4 and FY15 results

|About: EPIRUS Biopharmaceuticals,... (EPRS)|By:, SA News Editor

EPIRUS Biopharmaceuticals (EPRS) Q4 results: Revenues: $0.3M; R&D Expense: $10.6M (+120.8%); SG&A: $5.8M (+7.4%); Operating Loss: ($16.1M) (-57.8%); Net Loss: ($15.4M) (-48.1%); Loss Per Share: ($0.63) (+21.3%).

FY2015 results: Revenues: $0.6M; R&D Expense: $31M (+90.2%); SG&A: $21.9M (-4.8%); Operating Loss: ($52.4M) (-33.3%); Net Loss: ($52.2M) (-24.9%); Loss Per Share: ($2.30) (+66.2%); Quick Assets: $31.5M.

No guidance given.

Subscribe for full text news in your inbox